Literature DB >> 1350197

Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia.

P Riederer1, K W Lange, J Kornhuber, W Danielczyk.   

Abstract

Dopamine appears to be of less importance in the regulation of psychomotor functions than was previously thought. A central dopaminergic-glutamatergic balance may be important for both akinetic motor disorders and psychosis. In Parkinson's disease glutamate antagonists may counteract central glutamatergic hyperactivity and may be of value as anti-parkinsonian drugs. An increase of dopaminergic activity and/or a reduction of glutamatergic activity may contribute to the development of paranoid hallucinatory psychosis in schizophrenic patients and of pharmacotoxic psychosis in Parkinson's disease. Because of possibly severe side-effects of glutamatergic antagonists and agonists in the treatment of akinesia and psychosis, the development of partial glutamate agonists/antagonists could be an alternative strategy capable of producing antipsychotic or anti-kinetic effects with only mild adverse reaction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350197

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  11 in total

1.  Acetylcholine becomes the major excitatory neurotransmitter in the hypothalamus in vitro in the absence of glutamate excitation.

Authors:  A B Belousov; B F O'Hara; J V Denisova
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

2.  Further evidence for the subsensitivity of striatal AMPA receptors, induced by chronic haloperidol administration: an autoradiographic study.

Authors:  K Ossowska; M Pietraszek; J Wardas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

Review 3.  Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.

Authors:  C Mehler-Wex; P Riederer; M Gerlach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

4.  Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies.

Authors:  J Kornhuber; C G Parsons; S Hartmann; W Retz; S Kamolz; J Thome; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1995

5.  Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice.

Authors:  A Fredriksson; C Gentsch; T Archer
Journal:  J Neural Transm Gen Sect       Date:  1994

6.  N-methyl-D-aspartate (NMDA) antagonists in Parkinson's disease.

Authors:  J Kornhuber; P Riederer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

7.  Clozapine improves dizocilpine-induced delayed alteration impairment in rats.

Authors:  W Hauber
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2.

Authors:  M G Morgese; T Cassano; S Gaetani; T Macheda; L Laconca; P Dipasquale; L Ferraro; T Antonelli; V Cuomo; A Giuffrida
Journal:  Neurochem Int       Date:  2008-11-01       Impact factor: 3.921

9.  Developmental exposure to concentrated ambient ultrafine particulate matter air pollution in mice results in persistent and sex-dependent behavioral neurotoxicity and glial activation.

Authors:  Joshua L Allen; Xiufang Liu; Douglas Weston; Lisa Prince; Günter Oberdörster; Jacob N Finkelstein; Carl J Johnston; Deborah A Cory-Slechta
Journal:  Toxicol Sci       Date:  2014-04-01       Impact factor: 4.849

Review 10.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.